Thymidylate synthase expression levels: A prognostic and predictive role in advanced colorectal cancer

Oncology Reports

Volumn 14, Issue 3, 2005, Pages 657-662

  Bendardaf, R ^a,b   Lamlum, H ^a,b   Elzagheid, A ^a,b   Ristamaki R ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Colorectal carcinoma; Immunohistochemistry; Prognosis; Thymidylate synthase; Treatment response

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROTEIN BCL 2; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 24644475315     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.3.657     Document Type: Article

References (30)

1. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S and Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12: 2035-2042, 1994. (Pubitemid 24356018)
2. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
3. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998. (Pubitemid 28213336)
4. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4: 1227-1234, 1998. (Pubitemid 28213334)
5. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998. (Pubitemid 28070481)
6. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6: 1378-1384, 2000. (Pubitemid 30226223)
7. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
8. Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, et al: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31A: 1306-1310, 1995.
9. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, et al: Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21: 406-412, 2003. (Pubitemid 46606467)
10. Suda Y, Kuwashima Y, Tanaka Y, Uchida K and Akazawa S: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res 19: 805-810, 1999. (Pubitemid 29168335)
11. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M and Sato I: Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 57: 50-54, 1999.
12. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Toren JS, Tveit KM, et al: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first line therapy in advanced colorectal cancer. Ann Oncol 13: 1868-1873, 2002. (Pubitemid 36040775)
13. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
14. Royce ME, Hoff PM and Pazdur R: Progress in colorectal cancer chemotherapy: how far have we come, how far to go? Drugs Aging 17: 201-216, 2000.
15. Midgley R and Kerr D: Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 10: 1011-1019, 2001. (Pubitemid 32519681)
16. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998. (Pubitemid 28510874)
17. Rougier P, van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998. (Pubitemid 28510873)
18. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
19. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000. (Pubitemid 30215157)
20. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6: 488-492, 2000. (Pubitemid 30111468)
21. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, et al: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832-2843, 2002. (Pubitemid 34651512)
22. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E and Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5: 34-40, 1999. (Pubitemid 29108644)
23. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999. (Pubitemid 29269245)
24. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G et al: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil Clin Cancer Res 5: 1996-1999, 1999. (Pubitemid 29399249)
25. Davies MM, Johnston PG, Kaur S and Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5: 325-328, 1999. (Pubitemid 29085185)
26. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997. (Pubitemid 27419335)
27. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, et al: Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 64: 435-442, 2003. (Pubitemid 36682959)
28. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990. (Pubitemid 120029101)
29. Leahy DT, Mulcahy HE, O'Donoghue DP and Parfrey NA: bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 35: 360-367, 1999. (Pubitemid 29502355)
30. Sobin LH and Greene FL: TNM classification: clarification of number of regional lymph nodes for pNo. Cancer 92: 452, 2001. (Pubitemid 32664454)